Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 10/20 | 0.64 |
| ▸ | KDR | P35968 | 5/20 | 0.64 |
| ▸ | JAK2 | O60674 | 2/20 | 0.64 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.64 |
| ▸ | CDK1 | P06493 | 2/20 | 0.64 |
| ▸ | ROS1 | P08922 | 2/20 | 0.64 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.64 |
| ▸ | CDK2 | P24941 | 2/20 | 0.64 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.64 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.64 |
| ▸ | CLK2 | P49760 | 2/20 | 0.64 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.64 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.64 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.64 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.64 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.64 |
| ▸ | CDC7 | O00311 | 1/20 | 0.64 |
| ▸ | PLK4 | O00444 | 1/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14693624 | 1.00 | SRC (0.64) | SRCKDRJAK2DYRK3CDK1 | |
| SCHEMBL4821519 | 1.00 | SRC (0.64) | SRCKDRJAK2DYRK3CDK1 | |
| Hydrochloric Acid SCHEMBL4826416 | 0.99 | SRC (0.63) | SRCKDRJAK2DYRK3CDK1 | |
| SCHEMBL4826019 | 0.92 | SRC (0.62) | SRCKDRJAK2DYRK3CDK1 | |
| SCHEMBL13860277 | 0.92 | SRC (0.62) | SRCKDRJAK2DYRK3CDK1 | |
| SCHEMBL4822878 | 0.92 | SRC (0.71) | SRCKDRJAK2DYRK3CDK1 | |
| Hydrochloric Acid SCHEMBL17770592 | 0.91 | SRC (0.60) | SRCKDRJAK2DYRK3CDK1 | |
| Hydrochloric Acid SCHEMBL4824866 | 0.91 | SRC (0.60) | SRCKDRJAK2DYRK3CDK1 | |
| Hydrochloric Acid SCHEMBL17911530 | 0.91 | SRC (0.60) | SRCKDRJAK2DYRK3CDK1 | |
| Hydrochloric Acid SCHEMBL29720770 | 0.91 | SRC (0.70) | SRCKDRJAK2DYRK3CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115785103-A | Synthetic method of medicine fubatinib for treating bile duct cancer | 北京康立生医药技术开发有限公司 | 2023-03-14 | — | — | CN | claimed |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| CN-115485281-B | FGFR and mutation inhibitor thereof, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| CN-116514806-A | Biological inhibitor containing acrylketone, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-08-01 | — | — | CN | disclosed |
| EP-4169922-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| CN-115785103-A | Synthetic method of medicine fubatinib for treating bile duct cancer | 北京康立生医药技术开发有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-115785103-A | Synthetic method of medicine fubatinib for treating bile duct cancer | 北京康立生医药技术开发有限公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-115485281-A | FGFR and mutation inhibitor thereof, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2022033532-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
| WO-2022033532-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | FGFR3, FGFR1, FGFR4 | SRC 100/4885KDR 85/4885JAK2 21/4885 |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | SRC 30/4885KDR 24/4885JAK2 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.